Nepsis Inc. Decreases Holdings in Amgen Inc. $AMGN

Nepsis Inc. decreased its position in Amgen Inc. (NASDAQ:AMGN) by 11.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,314 shares of the medical research company’s stock after selling 6,684 shares during the quarter. Amgen accounts for 4.4% of Nepsis Inc.’s portfolio, making the stock its 12th largest position. Nepsis Inc.’s holdings in Amgen were worth $13,916,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Wealth Quarterback LLC boosted its stake in shares of Amgen by 1.6% in the 3rd quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock valued at $624,000 after purchasing an additional 34 shares in the last quarter. Fairvoy Private Wealth LLC lifted its stake in Amgen by 1.1% in the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock worth $885,000 after purchasing an additional 35 shares during the last quarter. Nicholson Wealth Management Group LLC boosted its position in Amgen by 0.6% during the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock valued at $1,652,000 after buying an additional 35 shares during the period. LS Investment Advisors LLC grew its stake in shares of Amgen by 4.1% during the third quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company’s stock valued at $250,000 after buying an additional 35 shares during the last quarter. Finally, Crown Wealth Group LLC increased its holdings in shares of Amgen by 4.0% in the third quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company’s stock worth $257,000 after buying an additional 35 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the sale, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. 0.76% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AMGN. Cantor Fitzgerald increased their target price on Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Morgan Stanley lowered their price objective on Amgen from $329.00 to $304.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. The Goldman Sachs Group restated a “buy” rating on shares of Amgen in a report on Tuesday, November 25th. Argus upped their price target on shares of Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a report on Tuesday, December 30th. Finally, Piper Sandler increased their price target on shares of Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Amgen has an average rating of “Moderate Buy” and a consensus target price of $338.55.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: UBS upgraded Amgen (AMGN) to a “strong-buy,” a direct bullish analyst signal that can support the stock. UBS upgrade: Amgen to strong-buy
• Positive Sentiment: Amgen struck an exclusive deal with Disco/Disco Pharma tied to a cancer target (deal worth up to $618M), which strengthens Amgen’s oncology pipeline and future revenue optionality. Amgen Disco oncology pact
• Positive Sentiment: Amgen completed a Phase 1b blinatumomab study in Japan, advancing its leukemia strategy — a clinical progress update that can de-risk a program and support long-term value. Blinatumomab study completed in Japan
• Neutral Sentiment: Truist nudged Amgen’s price target slightly higher (from $318 to $319) but kept a “hold” rating — a mild signal that doesn’t materially change sell-side sentiment. Truist raises AMGN price target to $319
• Neutral Sentiment: Citi reiterated a “hold” on Amgen, indicating continued analyst caution despite pipeline wins. Citi sticks to hold for Amgen
• Neutral Sentiment: Market/sector context: Amgen is tracking with the Nasdaq life-sciences segment and will be in focus at the JPMorgan Healthcare Conference, where peers typically reveal pipeline updates and M&A intent — a neutral-to-positive thematic tailwind depending on conference takeaways. AMGN aligns with Nasdaq life sciences
• Neutral Sentiment: Sector preview: CNBC notes JPMorgan Healthcare will drive pipeline/M&A headlines across big pharmas — Amgen may benefit if it announces high-impact deals. What to expect from pharma at JPM
• Negative Sentiment: Despite the positive deal and clinical updates, shares fell amid a broader market uptick and profit-taking; a Zacks note highlighted recent intraday weakness, reflecting short-term selling pressure. Amgen stock falls amid market uptick

Amgen Stock Performance

Shares of AMGN stock opened at $326.10 on Friday. The firm has a market capitalization of $175.60 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 3.00 and a beta of 0.45. The stock has a fifty day moving average of $329.75 and a 200 day moving average of $304.30. Amgen Inc. has a 52 week low of $260.55 and a 52 week high of $346.38. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same period in the prior year, the business earned $5.58 EPS. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.1%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 73.57%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.